Anti-cancer

Fulvestrant

CAS No. 129453-61-8

A selective estrogen receptor degrader (SERD) used in injectable oncology formulations for hormone-receptor-positive breast cancer.

Fulvestrant is a targeted estrogen-receptor-degrading oncology API manufactured by NovaAcura Biotech under GMP-certified conditions. Full batch documentation and regulatory support are available for global oncology formulation partners.

Applications & Uses

A selective estrogen receptor degrader (SERD) used in injectable oncology formulations for hormone-receptor-positive breast cancer.

Full technical documentation, batch specifications and regulatory support (DMF/CEP) are available on request.

Need This Molecule at Scale?

Get in touch for pricing, lead times and full regulatory documentation.

Get In Touch